Hanmi’s 3-sbustance combination drug containing Amosartan & rosuvastatin represented at EHS

2 case results of clinical trial for ‘Amosartan,’ a combination drug developed by Hanmi Pharm, were announced at the European Society of Hypertension(ESH).

Hanmi Pharm announced on the 20^th that it presented a Phase 3 clinical trial result of the 3-substance combination drug containing the Amosartan substance and hyperlipidemia substance and a study result of excellent blood pressure dropping ...